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Meningococcal disease remains a worldwide problem (1). Approximately 2,000 
sporadic cases occur yearly in the United States, and outbreaks have recently 
occurred in other countries (2-4).  Group B Neisseria  meningitidis is currently 
responsible for most meningococcal infections in the United States (5), England 
(6), and Europe.  Though effective polysaccharide vaccines for meningococcal 
groups A and C have been licensed, an immunogenic group B polysaccharide 
vaccine is not available  (7). This has necessitated examination of other cell 
components against which protective antibodies may be elicited (8, 9). 
Reports  of increased  susceptibility  to  Neisserial  infection  in  individuals 
lacking one of the higher complement components (10), but not in those with 
chronic neutropenia (11), indicate that bactericidal  antibody is  required for 
protection  against  meningococcal  disease  (12). Much  of the  anti-group  B 
bactericidal antibody is directed against protein serotype antigens (STA)  ~ (13, 
14). A synergistic protective effect exists between the group B polysaccharide 
and serotype antibodies (15), suggesting that combined vaccines may afford the 
best protection. 
Group B  meningococci have  been  subdivided into  a  number of serotypes 
based  on the presence of immunologically distinct STA  (13, 16). The  major 
outer membrane proteins of each of the serotypes probably contain the antigenic 
moiety responsible for type specificity (16). The serotype 2 antigen was chosen 
for initial  vaccine trials  because this serotype is  frequently associated with 
meningococcal disease (6, 17, 18). 
These studies describe the methods for preparation of immunogenic type 2 
protein vaccines, and their evaluation in a guinea pig chamber implant model 
(19). The vaccines were immunogenic and protected against infection by the 
* A  portion  of this  investigation  was  conducted  at  the  Rockefeller University  and  was 
supported by the U. S. Army Medical Research and Development Command, Research Contract 
DADA 17-70-C-0047, and by Public Health Service grant NS-11863 from the National Institute of 
Neurological Diseases and Stroke, National Institutes of Health, Bethesda, Md 20014. 
~Abbreviations  used  in  this  paper:  DOC,  deoxycholate;  EBC-720,  Emulphogene  BC-720; 
ELISA, enzyme-linked immunosorbant  assay;  HBSS-BSA,  Hanks'  balanced  salt  solution con- 
taining  0.1% bovine  serum  albumin;  KDO,  2-keto-deoxyoctonate;  LAL,  Limulus  amoebocyte 
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homologous  meningococcal  serotype  regardless  of  serogroup.  These 
elaborate upon findings presented in a  preliminary report  (20). 
studies 
Materials and Methods 
Strains and Growth Conditions.  The group B, type 2 meningococcal strains used were M986 
and  a  noncapsular  variant  of M986 designated  M986-NCV-1.  Meningococcal  strains  used  for 
guinea pig challenge, growth conditions,  and method of  challenge have been described (19).  For 
vaccine preparation the strains were grown either  in 12 2.8L baffled Fernbach flasks (Bellco 
Glass, Inc.,  Vineland,  N. J.) containing 1.4 liters  tryptic  soy broth (TSB, Difco Laboratories, 
Detroit,  Mich.) each, or in a 50-1iters  fermentor. In the first  method the cultures  were incubated 
overnight at 36°C at 125 rpm on a gyrotory shaker, then harvested by centrifugation.  For the 
fermentor procedure, the NCV-1 strain  was grown for  6 h in two Fernbach flasks  (1.4  liters  TSB 
oech),  then inoculated to  45  liters  of  TSB in the fermentor. The organisms were grown overnight 
at 37°C with 40 liters  air/rain  by sparge and agitation  of  200 rpm. The cells  were harvested from 
the  fermentor  with  a Sharples continuous flow centrifuge.  (Sharples-Stokes  Div.,  Pennwalt Corp., 
Warminster, Pa.) 
Preparation of Vaccines.  The starting material for vaccine preparation was the serotype 2 
STA, purified from 0.2 M  LiCI-0.1 M  Na Acetate, pH 5.8,  extracts by ultracentrifugation  as 
previously described (8).  Vaccines were prepared by three different  procedures: (a)  The STA was 
suspended to a protein concentration of i-2 mg/ml in 0.01 M  Tris (hydroxy methyl) amino- 
methane-HC1 0.01 M (ethylenedinitrilo)-tetraacetic acid buffer pH 8.5 (Tris-EDTA)  and treated 
with 5%  (vol/vol) Triton X-100 (TX-100) for 30 min at room temperature.  The serotype protein 
was pelleted by centrifugation at 100,000 g for 4 h, resuspended in Tris-EDTA buffer containing 
2%  (vol/vol)  TX-100 and  reultracentrifuged.  The  pellet  was  resuspended  in  0.15 M  sodium 
chloride and the protein precipitated, with 4 vol of 95% ethanol at -20°C overnight. The antigen 
was then treated with acetone at room temperature for 1 h to effect sterilization. The pellet was 
washed with ethanol to remove acetone. The vaccine was prepared by suspending the pellet in 
sterile 0.15 M sodium chloride at 1 mg/ml protein. (b) The initial solubilization and centrifugation 
procedures were exactly as  above,  except for substitution  of Emulphogene BC-720 (EBC-720, 
GAF Corp.,  New York)  in place of TX-100. After the initial detergent treatment,  the antigen 
preparation was ultracentrifuged twice in 2% detergent.  The pellet was dissolved in the Tris- 
EDTA buffer containing  0.5  M  sodium  chloride and  5%  (vol/vol)  EBC-720,  prefiltered,  then 
passed through an 0.22 ~m membrane filter (Millipore Corp., Bedford,  Mass.).  The protein was 
recovered by addition of 4 vol of 95% ethanol previously passed through an 0.2  ~m Nucleopore 
filter (Nucleopore  Corp., Pleasanton, Calif.). The pellet was washed twice with filtered ethanol 
and  resuspended  as final vaccine to approximately  1 mg protein/ml in sterile 0.15 M sodium 
chloride. (c) The STA was treated with 1% (wt/vol) deoxycholate (DOC, Sigma Chemical Co., St. 
Louis,  Mo.) in  1 mM Tris-HC1,  I0  mM EDTA pH  8.5  for 30  rain  at room temperature.  The 
serotype protein was then pelleted by centrifugation at 100,000 g for 4 h. The pellet was washed 
once with 1 mM Tris-EDTA buffer containing 0.1% DOC. Alternatively, the STA was solubilized 
in  DOC,  then  separated  by  gel  filtration  on  Sephadex  G150 (Pharmacia  Fine  Chemicals, 
Piscataway, N. J.) in the Tris-EDTA buffer containing 0.5% DOC. The STA eluted at the void 
volume and  was  recovered by  ethanol  precipitation  (80% vol/vol). The  protein  antigen  was 
resuspended  in Tris-EDTA buffer containing 2% DOC  and heated for 30 min in a  56°C water 
bath, then sterile filtered. The antigen was precipitated and washed as described for the EBC- 
720 vaccines. 
Chemical and Pyrogenic Analysis of Vaccines.  Protein was measured by method of Lowry et 
al. (21) with bovine serum albumin (fraction V) as a standard. Protein composition  was examined 
by sodium dodecyl sulfate-pelyacrylamide gel electrophoresis  (SDS-FAGE)  (8).  Lipepelysaccha- 
ride (LPS) was measured by 2-keto-deoxyoctonate (KDO) determination  (22)  with KDO  (Sigma 
Chemical Co.)  as a standard. Amino acid analysis was determined after  hydrolysis at 115°C in 6 
N  hydrochloric acid for 22 h. Sialic  acid content was estimated on a Beckman  amino acid 
analyzer  (Beckman  Instruments,  Inc., Cedar Grove, N. J.) after mild acid hydrolysis (23). 
Nucleic acids  were determined by examination for ribose  by the method of Boykins and Liu 
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The vaccines were tested for endotoxin content by the Limulus amoebocyte lysate gelatin test 
(LAL) using a Klebsiella LPS reference standard (24, 25). In some experiments meningococcal 
LPS prepared from strain M986 by hot phenol-water (8) was used as a standard. Selected vaccine 
lots were also examined for rabbit pyrogenicity with the standard U.  S. Pharmacopoeia rabbit 
test and for a dermal Shwartzman reaction (26). 
Immunization and Challenge of Guinea Pigs.  The antibody response to the different vaccines 
was evaluated in 250-500 g female NIH Hartley strain guinea pigs. The animals were injected 
intramuscularly with different doses of vaccine in 0.1 ml saline. This was usually followed by a 
booster given 2-3 wk later.  The protective effects of immunization were examined using the 
stainless steel chamber implant model of Arko and Frasch and Robbins (27, 19). The guinea pigs 
were challenged 10-14 days after implantation with approximately 5 x 10  ~ log phase meningococci 
injected into the spring chamber. The animals were sampled and bled as before (19). 
Quantitation of Serotype Antibody.  Enzyme-linked immunosorbant assay (ELISA) was used 
for quantitation of serotype antibodies (28). Serum IgG from a guinea pig immunized with an 
EBC-720 vaccine was prepared by ion exchange chromatography on Whatman DE-52 (Whatman 
Chemicals Div. W & R Balston, Maidstone, Kent, England) in 0.02 M Tris-HC1 pH 8.2.  Serum 
dialyzed against this buffer was applied to the column.  The IgG eluting in the fall-through 
volume was quantitated assuming an extinction coefficient of 1.4 at 280 nm.  Purity of the IgG 
was evaluated by Microzone electrophoresis on acetate strips (Beckman Instruments, Inc., Palo 
Alto, Calif.). We labeled 150 ~g of this IgG fraction with 125I using the chloramine-T method of 
Greenwood et al. (29). The percentage of IgG bound to type 2 STA immobilized on the surface of 
10  x  75-ram  polystrene tubes  (Falcon Plastics,  Div.  of BioQuest,  Oxnard,  Calif.) was  then 
determined at five different IgG concentrations, from which the concentration of type 2 antibody/ 
ml was calculated. A standard curve for each ELISA was plotted, relating absorbance at 400 nm 
at 100 rain to nanogram antibody in the IgG standard. 
Bactericidal Assay.  A modification of the microbactericidal assay (13) was used for measure- 
ment of bactericidal antibody in selected guinea pig sera. The sera were titrated in flat bottom 
microtissue culture trays  (Falcon Plastics, model 3040), using Hanks' balanced salt solution 
containing 0.1% bovine serum albumin (HBSS-BSA) as diluent. The meningococci were grown to 
log phase (4-5 h) on the surface of brain-heart infusion plates, then diluted to 78% transmission 
at 540  nm  in phosphate-buffered saline (PBS) pH 7.4.  The organisms were further diluted to 
yield approximately 2,000 organisms/ml, the final dilution being in HBSS-BSA. The source of 
complement  was  4-wk-old baby rabbit serum  (type 3,  Pel-Freez Farms,  Inc.,  Rogers,  Ark.) 
diluted 1:2. The trays were incubated at 37°C for 30 rain, approximately 0.2 ml of TSB  (Difce 
Laboratories) containing 1.2% Noble agar (Difco Laboratories) at 45°C was added to each well, 
and further incubated 24 h  at 37°C, then read. The endpoint was the highest serum dilution 
causing 50% or greater reduction in viable count. 
Results 
Preparation and Analysis of Protein Vaccines.  The STA complex contains 
similar  amounts  of protein  and  LPS  (16).  The  type  2  STA  was  treated  with 
detergents  to preferentially  solubilize the toxic LPS component.  While TX-100 
nonspecifically  solubilized  both  the  LPS  and  protein  components,  EBC-720 
preferentially solubilized the LPS.  The major 41,000  dalton protein component 
of the outer membrane  remained  within  the high molecular weight complexes 
after treatment  of the  STA with  5%  EBC-720  in  the  low ionic strength  Tris- 
EDTA  buffer.  Upon  removal  of detergent,  most  vaccine preparations  became 
particulate. 
Various methods  were investigated  for sterilizing the STA vaccines without 
altering  their  immunologic  properties.  In  preliminary  experiments,  small 
vaccine lots prepared  using TX-100 were  treated  with  acetone,  but this treat- 
ment  did not sterilize all lots, since acetone does not kill bacterial spores  (30). 
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detergent-treated ultracentrifugation pellet was resuspended in 5% EBC-720 in 
Tris-EDTA buffer containing 0.5 M sodium chloride. 
EBC-720,  TX-100,  and  DOC  vaccines,  prepared  from  different batches  of 
M986, were compared with an untreated STA by SDS-PAGE (Fig. 1). Solubility 
of the different proteins of the STA complex varied with the detergent used. 
DOC-treated vaccines generally contained primarily the major 41,000  dalton 
protein.  The TX-100 and EBC-720  vaccines were approximately 86%  protein, 
while the DOC prepared vaccines contained up to 97% protein (Table I).  LPS 
was the only other significant component detected in the vaccines.  Group B 
polysaccharide was not detected and no nucleic acids were detected. 
The  endotoxin  (i.e.  LPS)  content of the  vaccines was  estimated by  KDO 
content,  the  LAL  gelation  test,  and  by  rabbit  pyrogenicity  (Table  I).  The 
amount of endotoxin detected by LAL was considerably less  (10- to 200-fold) 
than that calculated from the KDO  content. A Klebsiella LPS was regularly 
used as a standard for LAL. The sensitivity of the assay was the same using a 
meningococcal LPS standard.  The different results with the two methods are 
most  likely explained by the particulate  nature of the vaccines,  since LAL 
probably  detects  only  the  endotoxin  on  the  particle  surface.  Some  antigen 
preparations  (not  shown  in  tables)  remained nonparticulate  after detergent 
treatment,  and  in  these  preparations  the  LAL  test  gave  endotoxin  values 
comparable to those obtained by KDO determinations. The rabbit pyrogenicity 
determinations agreed very well with  the  LAL  results,  indicating that  the 
rabbits also respond primarily to the surface endotoxin. 
The DOC  and EBC-720  vaccines were further characterized by amino acid 
analysis and compared to that of the untreated STA (Table II). The glucosamine 
content varied in direct proportion to the amount of LPS present, and therefore 
can be used to estimate the amount of LPS in vaccines. Phenol-water purified 
LPS of the vaccine strain contained 3.3% glucosamine (C. E. Frasch and J.  D. 
Robbins, unpublished data). 
Quantitation of Antibody Response.  Due to the amount of serum available 
and the protein nature of the antigen, antibody measurements were not done 
by the quantitative  precipitin  method.  For  quantitation  of the  type 2  STA 
antibody,  an  IgG  fraction  of the  standard  serum  was  prepared  by  DEAE 
chromatography and compared to the unfractionated serum for serotype reactiv- 
ity by ELISA (Fig. 2 A). Most of the type specific antibody was present in the 
IgG  fraction.  Comparison  of labeled  and  unlabeled  IgG  indicated  that  the 
labeling did not alter its serological reactivity. Finally, the percent of total IgG 
reacting with an excess of type 2 STA was determined. Over a series of twofold 
dilutions  of the IgG fraction from 1/50 to  1/800, the STA bound 2.94  _+  0.05 
percent of total IgG. The IgG standard was run with each ELISA experiment. 
The standard curve was linear between approximately 1 and  100  ng specific 
antibody (Fig. 2 B). 
Vaccine-Induced Antibody Response.  In all experiments, the vaccines were 
injected intramuscularly into the animal's thigh without adjuvants. First, the 
relative immunogenicity of untreated STA was compared to the EBC-720 and 
DOC vaccines (Fig. 3). Each vaccine was administered in two doses 2 wk apart, 
200  and  100  ~zg being given in the first and second doses,  respectively. The CARL  E.  FRASCH  AND  JOAN  D.  ROBBINS  633 
FIG. i.  Comparison of  the SDS-PAGE  patterns of  vaccines prepared by detergent treat- 
ment of  type 2 STA. The gel  patterns:  (1)  M986-NCV-1 STA; (2)  EBC-720 vaccine lot  E-05; 
(3)  TX-100 vaccine lot V-3;  (4) DOC  vaccine lot  VMF-1, prepared by ultracentrifugation; 
and (5)  a DOC  vaccine prepared by gel  filtration  on Sephadex G150. 634  PROTECTION  AGAINST  GROUP  B  MENINGOCOCCAL  DISEASE.  III 
TABLE  I 
Comparison  of Serotype 2 Vaccines Prepared from M986 and M986-NCV-1  with 
Different  Detergents 
~g LPS/mg Protein 
Vaccine lot  Detergent  Protein  LPS  MPD$ 
used  TBA*  LAL 
pg/mg  ~g/mg  /~gprotein 
STA  -  425  301  708  -§  - 
V-1  TX-100  840  160  190  -  - 
V-3  TX-100  860  140  163  10  0.9 
DOC-1  DOC  920  80  87  0.2  5.6 
D-1  DOC  970  30  31  -  - 
VMF-1  DOC  920  80  87  1.8  3.4 
E-1  EBC-720  870  130  75  5.0  - 
E-2  EBC-720  880  120  136  0.6  - 
E-3  EBC-720  860  140  158  -  - 
* TBA, Thiobarbituric acid assay. 
* MPD,  Minimum pyrogenic dose in  New Zealand white rabbits 
rabbit. 
§ Not done. 
represented as ~tg protein/kg 
TABLE II 
Amino Acid and Amino Sugar Composition of the Untreated Serotype 
2 Antigen and Type 2 Vaccines 
EBC-720 Vac-  Component  STA  DOC  Vaccine 
cine 
moles %* 
Lysine  8.53  10.28  8.02 
Histidine  2.51  2.79  2.17 
Arginine  6.17  6.51  5.31 
Aspartic acid  8.33  9.58  10.01 
Threonine  4.29  4.74  5.10 
Serine  6.15  6.66  6.93 
Glutamic acid  8.32  9.37  9.44 
Proline  1.86  1.86  2.37 
Glycine  10.50  10.50  11.59 
Alanine  8.35  9.64  11.59 
Cysteine  0.00  0.00  0.00 
Valine  6.90  8.13  8.76 
Methionine  1.09  0.95  1.09 
Isoleucine  2.81  2.94  3.08 
Leucine  4.34  4.81  4.94 
Tyrosine  4.59  5.59  4.63 
Phenylalanine  4.07  4.56  4.27 
Glucosamine  4.29  1.09  0.69 
* Amino acid composition not corrected for degradation. 
antibody  response  was  measured  2  and  approximately  5  wk  after  primary 
immunization.  Preimmunization  sera  contained  <0.1  /~g/ml  STA  antibody. 
The peak  mean  antibody  concentrations  were 88, 28,  and  13  ~g/ml  for the  STA, 
EBC-720,  and  DOC  vaccines,  respectively.  The  untreated  STA  proved  toxic to CARL  E.  FRASCH  AND  JOAN  D.  ROBBINS 
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FIG.  2.  Quantitation of specific antibody in an IgG fraction of an anti-serotype 2 guinea 
pig serum. (A) Comparison of binding curves for the DEAE prepared IgG from serum 9-P 
(O) with the whole 9-P serum (I) and another guinea pig immune serum, 7-G (&).  (B) A 
standard curve using the IgG fraction. 
the animals,  but animals injected with the detergent treated antigens showed 
no ill effects from either injection. 
To examine the primary immune response and determine whether a booster 
response would occur,  animals  were given a  50  keg dose of DOC vaccine,  Lot 
VMF-1 or VMF-2, and a  second dose 8 wk later.  Sera were obtained at 1-2-wk 
intervals  throughout  the  experiment  (Fig.  4).  The  primary  immunization 
resulted  in  a  slight  antibody  rise  of approximately  0.5  /~g  antibody/ml  (see 
Table  III).  The  second  dose  of vaccine  caused  a  rapid  6-  to  20-fold  rise  in 
antibody which persisted at elevated levels. The peak antibody response was 
comparable to that observed when vaccine doses were presented 2-3 wk apart. 636  PROTECTION  AGAINST  GROUP  B  MENINGOCOCCAL  DISEASE.  III 
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FIG.  3.  Serotype 2 antibody response measured by ELISA after immunization with type 
2 STA, TX-100 prepared vaccine, and DOC prepared vaccine. The vaccines were given in 
doses of 200 ~g at wk 0 and 100 ~g at wk 2. 
The various vaccine preparations  and doses used in the protection studies 
are listed in Table III. When administered in two doses, most vaccines elicited 
a mean of >25 ~g antibody/ml serum 5 wk after primary immunization. There 
was no correlation between LPS content of vaccines and antibody response. 
However, since all vaccines tested contained LPS to varying degrees, and the 
serotype 2 antigen used in ELISA was a lipoprotein-lipopolysaccharide complex, 
it was necessary to determine the relative antibody response to the individual 
protein  and  LPS  components  (Table  IV).  No  LPS  antibody  was  detected. 
Almost identical OD4oo values were obtained with the  STA  and a  relatively 
LPS-free protein antigen (vaccine lot E-02). 
To determine the most effective dosage, a TX-100 vaccine was used in a dose- 
response experiment (Fig.  5).  Groups of animals received two equal doses of 
vaccine 2 wk apart. The dose range was between 25 and 200  ~g protein. As a 
control, one set of animals received 100 ~g of group B polysaccharide attached 
to methylated bovine serum albumin for its adjuvant effect. For both primary 
and secondary immunizations, the 25  ~g dose elicited approximately as much 
antibody  as  did  the  higher  dosages.  In  animals  given  the  polysaccharide 
vaccine, no anti-capsular or serotype antibodies were detected by ELISA. CARL  E.  FRASCH  AND  JOAN  D.  ROBBINS  637 
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Fro.  4.  Anamnestic response of guinea pigs to a  second immunization with serotype  2 
vaccine.  Animals were immunized with 50-~g doses of vaccine VMF-1  (solid symbols) or 
vaccine VMF-2 (open symbols). Arrows denote when vaccines were administered. Antibody 
against the STA was measured by ELISA. 
Since  protection  against  meningococcal  disease  has  been  correlated  with 
presence  of bactericidal  antibodies  (10,  11,  28)  an  in  vitro  bactericidal  assay 
and ELISA were performed on sera obtained at 2-3 wk intervals after immuni- 
zation with two of the vaccines (Fig. 6). Both vaccines elicited peak bactericidal 
titers of 1:1,600 to 1:6,400. The antibody response curves obtained by bactericidal 
assay  and  by ELISA  were  similar,  indicating  that  the  same  antibody  was 
probably being measured in both assays. 
Vaccine-Induced Protection.  To  study  resistance  to  infection,  we  used  a 
guinea pig model in which subcutaneous spring chambers can be infected with 
small numbers of memingococci. Nonvaccinated animals eliminate their infec- 
tions in 12-14 days and clearance of infection is associated with appearance of 
circulating antibody (19). 
Experiments were designed to determine whether low antibody levels induced 
by  a  single  immunization  would protect  against  homologous  meningococcal 
challenge, and whether a subprotective immunization would have demonstrable 
effects upon the severity of infection (Table V). Animals were challenged with 
5  ×  l0  s bacteria of strain  S-946  3 wk after immunization.  50% of the animals 638  PROTECTION  AGAINST  GROUP  E  MENINGOCOCCAL  DISEASE.  III 
TABLE  III 
Antibody Response in Guinea Pigs to Different Serotype 2 Vaccine Preparations 
Dose  Mean 
Animal  No.  ani-  t~g LPS  ~g/ml  Range  set  mals  Vaccine lot Detergent used  per 
1  °  2 °  dose*  anti- 
body$ 
P4g protein 
1  4  STA  None  200  100  22  87.5  40-110 
2  4  E-1  EBC-720  200  100  16  28.0  14-39 
33  4  E-4  EBC-720  50  50  7  25.5  11-59 
8  4  T-1  TX-100  50  50  8  29.8  6-50 
9  4  T-1  TX-100  25  25  4  32.0  14-54 
24  4  V-3  TX-100  50  50  7  57.0  4-240 
14  4  D-1  DOC  100  100  3  13.0  7-21 
25  4  D-3  DOC  50  50  5  39.5  9-92 
32  4  D-4  DOC  50  50  10  45.8  13.5-65 
27  4  VMF-1  DOC  50  -  4  0.8  0.5-1.6 
28  4  VMF-2  DOC  50  -  2  0.3  0.2-0.4 
* LPS determined by analysis of KDO content of vaccine by TBA assay. 
$ Antibody determinations were done by ELISA on sera taken 5 wk after first immunization; the 
mean preimmunization value was <0.1  tLg/ml. 
TABLE  IV 
Specificity of Antibody Response Measured by ELISA in Guinea Pigs 5 Wk after 
Immunization with Serotype 2 Vaccines 
Animal set  Vaccine lot  Dose  t~g LPS per 
dose 
Mean OD4~ value with antigen* 
STA-Pro- 
STA  LPS 
tein 
P4g protein 
1  STA  150 
8  T-1  50 
24  V-3  50 
14  D-1  100 
25  D-3  50 
32  D-4  50 
22  3.56  1.97  0.02 
8  2.37  2.16  0.02 
7  2.26  1.96  0.03 
3  1.86  1.74  0.02 
5  1.87  1.44  0.02 
10  1.63  1.50  0.01 
* The OD4oo was calculated at 100 min for a  serum dilution of 1/400, 
who  received  25  or  50  t~g  of  serotype  vaccine  resisted  infection.  Even  in 
animals  that  received  only  1  t~g  of protein,  the  severity  of infection  was 
significantly altered as measured by numbers of bacteria in the chambers and 
duration of infection. 
The  degree  and  specificity  of  protection  were  examined  after  two-dose 
immunization  (Table  VI),  because  a  severalfold  greater  antibody  response 
occurred with two doses. Approximately 90% of animals were protected against 
serotype 2 strains regardless of serogroup, but 50% of animals challenged with 
heterologous  group  B  strains  were  also  resistant.  Resistance  to  infection 
persisted  for  at  least  4  mo  after  booster immunization.  Those  animals  that 
became infected with type 2 organisms had only low level infections  (ca 2,000 
organisms/milliliter  on day 2) that did not persist beyond day 4.  Animals that CARL  E.  FRASCH  AND  JOAN  D.  ROBBINS  639 
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FIG.  5.  Dose-response in guinea pigs to a TX-100 vaccine. Booster injections were given 2 
wk after primary immunization. One set of animals received two doses of 100 ~g of group 
B meningococcal polysaccharide conjugated to methylated bovine serum albumin. 
received  group  B  polysaccharide  were  not  protected,  which  correlates  with 
failure to detect antibody in these animals. 
Discussion 
Serotype 2 was chosen for initial vaccine development because of its associa- 
tion with meningococcal disease caused by groups B, C, Y, and W135 (17,  31), 
and its association with several meningococcal outbreaks, including the recent 
group C S~o Paulo epidemic (6,  18). 
It is important to standardize the culture conditions because the protein and 
LPS composition of the outer membrane may be altered by changes in growth 
conditions  (16).  The  vaccines  used  in  the  present  study  were  prepared  by 
detergent  treatment  of the  STA complex.  For selective removal of LPS from 
the  complex,  EBC-720  proved  best,  while  TX-100  was  the  least  selective. 
Analysis of vaccines for LPS by KDO content always yielded higher endotoxin 
values  than  did  either  the  Limulus  lysate  test  or rabbit  pyrogenicity.  This 
difference is probably due to the particulate nature of the vaccine. 
In dose-response experiments,  a  wide range of effective dosage was evident. 
As little as 1 ~g antigen stimulated detectable antibody levels. A single 50 ~g 
injection of vaccine elicited a peak antibody response at 3-4 wk of about 0.5 ~g! 
ml  serum though  it was insufficient to protect  more than  50%  of animals.  A 
second  immunization  2-8  wk  later  resulted  in  an  anamnestic  response  with 
mean peak antibody levels of 25-50 ~g/ml serum. Thus, a two-dose immuniza- 
tion schedule seems necessary to provide the best protection against challenge. 
All  vaccine  lots  elicited a  bactericidal  antibody response,  which  correlated 640  PROTECTION  AGAINST  GROUP  B  MENINGOCOCCAL  DISEASE.  III 
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FIG.  6.  Comparison of bactericidal titers and serotype 2 antibody response  measured by 
ELISA.  (A) Animals (set 33) were immunized with two 50-pg doses of EBC-720 vaccine lot 
E-4.  (B) Animals (set 32) were immunized with two 50-~g doses of DOC vaccine lot D-4. 
Arrows denote when vaccines were administered. 
closely with the ELISA values. Some lots of vaccine stimulated greater amounts 
of antibody than others. This variation in antibody response was not attributa- 
ble to adjuvant effects of the endotoxin, as there was no correlation with LPS 
content  of vaccine,  nor was  there  a  detectable  antibody  response  to  the  LPS 
after immunization.  The differences in antibody response to the different lots 
may  be  due  to yet  unknown  differences  in  their physical-chemical  structure 
resulting from detergent treatment. 
Guinea  pigs  immunized  with  the  serotype  2  protein  were  resistant  to 
challenge with type 2 organisms, regardless of their group specific polysaccha- 
ride. Some protection against heterologous group B strains was observed. This 
protection  may  be  related  to  the  cross-reactivity  of the  different  serotype 
antigens seen in an antigen binding assay  (16). CARL  E.  FRASCH  AND  JOAN  D.  ROBBINS  641 
TABLE  V 
Effects of a Single Dose Immunization  upon a Subsequent Meningococcal Infection 
(Strain $946) 3  Wk later 
Animal set  Vaccine lot 
Mean  se- 
rum bacte- 
Dose 
ricidal ti- 
ter* 
Animals infected/injected  on day (average organisms/milliliter) 
2  5  7  11 
l~  protein 
51  D-05  50  176  2/4 (4 x  104)  2/4 (4 ×  10')  i14 (6 x I0  ~)  014 
52  10  128  4/4 (6 × 104)  4/4 (1 × 104)  4/4 (8 × i0  a)  1/4 (4 × 10  s) 
53  1  40  4/4 (4  x  10  ~)  4/4 (1  ×  10  e)  4/4 (5  ×  106)  1/4  (1  ×  102) 
55  E-02  50  56  2/4 (4 x 104)  2/4 (7 x i0  ~)  1/4 (I x 10  s)  0/4 
56  25  81  2/4 (I × 104)  0/4  0/4  0/4 
57  10  22  3/4 (8 x 105)  2/4 (4 × 104}  2/4 (2 x 10  s)  1/4 (2 x 10  s) 
58  1  22  3/4 (7 × I0  ~)  3/4 (2 ×  10  ~)  3/4 (2 ×  i0')  0/4 
54  A/C$  50  <2  4/4  (3  ×  107)  4/4 (9  ×  108)  4/4 (7  x  106)  2/4 (7  ×  103) 
* The bactericidal titer  was deterrnined just before challenge using the group B type 2 strain BI6B6. 
A/C Meningococcal polysaccharide vaccine, groups A  and C combined. 
TABLE VI 
Resistance to Meningococcal  Infection  3-17 Wk after Immunization with Two Doses of 
Serotype 2  Vaccine 
Animal set  Vaccine lot  Dose 
Weeks aRer 
second immu- 
nization 
Challenge  with strain* 
S-946  S-1975  M1080 
138I  (C,2)  M982  (B,9) 
(B,2):t  (Y,2)  (B,1) 
p@ protein 
2  E-1  200  3  1/4§  -  -  1/3  - 
7  T-1  100  3  0/4  0/4  -  -  - 
8  T-1  50  3  0/4  I/4  -  - 
9  T-1  25  3  0/4  1/4  -  - 
3  D-2  200  3  0/4  -  -  2/4  - 
24  V-3  50  8  1/4  -  0/4  -  - 
33  E-4  50  9  0/4  -  -  -  2/4 
25  D-3  50  8  1/3  0/3  -  -  - 
32  D-4  50  9  0/3  -  -  2/3  - 
27  VMF-1  50  17  0/4  0/4  1/4  -  - 
Combination  type 2 vaccines  -  -  3/38(92)11  2/19(89)  1/8(88)  5/10(50)  2/4(50) 
10  B  polysaccharide  100  3  3/3  .... 
*  Challenge  dose approximately  3  ×  105 Meningecocci. 
$  (Serogreup,  serotype). 
§  Infected/challenged. 
II  Percent of animals protected. 
Meningococcal  disease  as  well  as  carriage  induce  high  levels  of serotype 
antibody  in  both  adults  and  children  (28,  32).  Presence  of elevated  serotype 
antibody levels in convalescent sera of infants after meningococcal disease  (28) 
indicated  that  the  STA  was  immunogenic in children  under  1 yr of age.  An 
STA vaccine may therefore protect very young children who are most suscepti- 
ble to meningococcal infection.  A  serotype 2 vaccine can be expected to protect 
against a significant proportion of disease caused by groups B, C, Y, and W135 
(31).  Successful application of serotype vaccines will depend upon identification 
of the serotypes responsible  for meningococcal  disease  in the population to be 
immunized.  The vaccine of choice may well contain multiple serotype proteins 
as well as group specific capsular polysaccharides  since there is evidence for a 
synergistic effect between protein and polysaccharide antibodies  (15). 642  PROTECTION  AGAINST  GROUP  B  MENINGOCOCCAL  DISEASE.  III 
Summary 
Protein  vaccines  were  prepared  from  the  serotype  antigen  of  group  B 
Neisseria meningitidis strain M986. The detergents Triton X-100, Emulphogene 
BC-720,  and  deoxycholate were  used  to  remove the  toxic lipopelysaccharide 
(LPS)  portion  of  the  serotype  antigen.  The  LPS  was  most  preferentially 
solubilized by  Emulphogene.  Guinea pigs  were  immunized with  one or two 
doses  of vaccine given  intramuscularly without adjuvants  and  the  antibody 
response quantitated by an enzyme-linked immunosorbant assay.  Immuniza- 
tion with graded doses of vaccine between 25 to 200 fig protein indicated a wide 
range  of effective dosage  and  that  a  two-dose  immunization  schedule  was 
superior  to  a  single  immunization.  The vaccines elicited peak  mean  serum 
~ntibody levels of approximately 30  ftg/ml with bactericidal titers of 1:1,600- 
1:6,400.  The peak  antibody levels  occurred  5-6  wk  after  immunization  and 
persisted above preimmune levels for several months. To evaluate the protective 
effects of immunization, stainless steel springs were implanted subcutaneously 
into the guinea pigs. The resulting chambers, in unimmunized animals, could 
be  infected with  less  than  100  type 2  organisms.  A  single  25-50  ~g  dose of 
vaccine protected 50% of animals from challenge by 5 x  105 type 2 meningococci, 
and as little as 1 /~g vaccine significantly reduced the severity of infection. A 
two-dose immunization schedule was best and provided nearly complete protec- 
tion for at least 4 mo against type 2 strains of meningococcal groups B, C, and 
Y. 
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